- Journal Article
Rights / licenseCreative Commons Attribution 4.0 International
While small‐molecule kinase inhibitors became the most prominent anticancer drugs, novel combinatorial strategies need to be developed as the fight against cancer is not yet won. We review emerging literature showing that the release of several ectokinases is significantly upregulated in body fluids from cancer patients and that they leave behind their unique signatures on extracellular matrix (ECM) proteins. Our analysis of proteomic data reveals that fibronectin is heavily phosphorylated in cancer tissues particularly within its growth factor binding sites and on domains that regulate fibrillogenesis. We are thus making the case that cancer is not only a disease of cells but also of the ECM. Targeting extracellular kinases or the extracellular signatures they leave behind might thus create novel opportunities in cancer diagnosis as well as new avenues to interfere with cancer progression and malignancy. Show more
Journal / seriesCancer Medicine
Pages / Article No.
SubjectCancer marker; Drug design; Ectokinases; Exokinases; Extracellular matrix; Extracellular phosphorylation; Extracellular protein kinase; Personalized medicine
Organisational unit03640 - Vogel, Viola / Vogel, Viola
MoreShow all metadata